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Abstract After more than 25 years of research and
development, in October 2006 ArteFill
  became the ﬁrst
and only permanent injectable wrinkle ﬁller to receive
FDA approval. ArteFill is a third-generation polymeric
microsphere-based ﬁller, following its predecessor Art-
ecoll
 , which was marketed outside the United States
between 1994 and 2006. ArteFill is approved for the cor-
rection of nasolabial folds and has been used in over 15,000
patients since its U.S. market introduction in February
2007. No serious side effects have been reported to date
according to the FDA’s MAUDE reporting database. Ar-
teFill consists of polymethylmethacrylate (PMMA)
microspheres (20% by volume), 30–50 lm in diameter,
suspended in 3.5% bovine collagen solution (80% by
volume) and 0.3% lidocaine. The collagen carrier is
absorbed within 1 month after injection and completely
replaced by the patient’s own connective tissue within
3 months. Each cc of ArteFill contains approximately six
million microspheres and histological studies have shown
that long-term wrinkle correction consists of 80% of the
patient’s own connective tissue and 20% microspheres.
The standard injection technique is subdermal tunneling
that delivers a strand of ArteFill at the dermal–subdermal
junction. This strand beneath a wrinkle or fold acts like a
support structure that protects against further wrinkling and
allows the diminished thickness of the dermis to recover to
its original thickness.
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The ﬁrst commercially successful, FDA-approved inject-
able ﬁller for soft tissue augmentation was a solution of
soluble collagen [1, 2] marketed by Collagen Corporation
in 1983. Until then, the only widely used ‘‘off-the-shelf’’
injectable ﬁller had been liquid dimethylpolysiloxane (sil-
icone). Complications from liquid silicone (LIS), however,
were often disﬁguring and challenging to correct.
Collagen injections, on the other hand, were never held
out as permanent corrective devices for the treatment of
soft tissue defects, whether scar depressions, atrophy, or
wrinkle lines. The corollary mantras ‘‘temporary solution,
but temporary problems’’ (if an adverse event should
occur), and ‘‘permanent solution, permanent problems’’
were associated with collagen and silicone, respectively.
However, although both patients and physicians accepted
the inconvenience and repeated expense of short-term
ﬁllers, they have long sought a dermal ﬁller substance that
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DOI 10.1007/s00266-009-9413-1promised long-lasting results with extremely low inci-
dences of complications and adverse events. With the
development of ArteFill
  (Suneva Medical, San Diego,
CA), a viscous liquid of polymethylmethacrylate (PMMA)
microspheres suspended in solubilized bovine collagen,
and its approval by the FDA in 2006, a long-lasting sub-
dermal ﬁller is now lawfully available.
Development History
ArteFill Precursors
The PMMA/collagen predecessor to ArteFill was ﬁrst
developed by the senior author in Germany more than
20 years ago, and his persistent efforts led to the current
(third generation) product, ArteFill [3]. The combination of
two widely used and proven biocompatible materials,
bovine collagen (sutures, hemostatic agents, implants) and
PMMA (orthopedic bone cement, craniectomy plates),
satisﬁes biocompatibility issues. The microscopically small
particles of PMMA in the bovine collagen carrier are
enveloped by autologous collagen as the byproduct of
natural connective tissue turnover, leaving a pliable, and
permanent, tissue residual.
After seeking the optimal collagen/PMMA ratios in
laboratory animals, trials on humans were initiated. The
ﬁrst-generation product, called Arteplast
 , as well as its
successor, Artecoll
 , proved efﬁcacious, although adverse
events did emerge [3–5]. Most of these adverse events were
ﬁrm nodularities at injection sites, occasionally with an
associated inﬂammatory response. In several instances,
surgical removal of the implant was required.
Further investigation led to the conclusion that there is a
speciﬁc threshold of PMMA microsphere size that is crit-
ical to avoid phagocytosis by macrophages and giant cell
formation with resulting granulomatous inﬂammation.
Associated observations suggested that small PMMA
microspheres, less than 20 lm in diameter, engendered a
foreign body response [6]. ArteFill embodies the lessons
learned from both the Arteplast and Artecoll experiences.
Biocompatibility
The key to ArteFill’s biocompatibility and safety, as doc-
umented in animal experiments [7], is the extremely uni-
form, round and smooth PMMA microspheres [3], and
especially the absence of particles less than 20 lmi n
diameter (Fig. 1). The novel puriﬁcation process estab-
lished for the production of the ﬁnal product explains the
absence of documented granulomas with ArteFill in over
15,000 patients. These observations differ from the gran-
uloma rates reported after the injection of ﬁrst-generation
Arteplast and second-generation Artecoll [6]. In those
cases, host cellular reaction was histologically attributed to
PMMA impurities and PMMA particles smaller than
20 lm that could be phagocytized [7]. In the earlier pro-
cessing of the PMMA microspheres, the small particles
appeared to adhere to the larger microspheres during the
sieving step, probably due to electrostatic charges.
The smooth surface morphology of ArteFill’s PMMA
microspheres also appears to mitigate an inﬂammatory
response. Microscopically, macrophages and foreign body
giant cells, also called ‘‘frustrated macrophages,’’ can be
detected around particles with an irregular surface [8]. This
may explain the rather high rate of granulomas after
injection of Dermalive
 , whose particles are characterized
by an irregular, rugged surface [6]. It has also been
observed that spiculated and small, irregular particulate
materials such as polyurethane foam and the silicone par-
ticles on the surface of textured breast implants often elicit
a chronic granulomatous tissue reaction [6].
Histology
ArteFill, as with implantation of any particulate material in
humans, invariably elicits an initial foreign body reaction.
As with normal wound healing, the initial event consists of
a tissue-material interaction whereby serum proteins
(ﬁbronectin and ﬁbrinogen) are deposited at the micro-
sphere surface. The next event is the invasion of neutro-
phils and monocytes, which release their granular
Fig. 1 ArteFill consists of 20% PMMA microspheres, 30–50 lmi n
diameter, that are suspended in 80% mostly denatured bovine
collagen
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123components and rapidly differentiate into macrophages.
They attach to the microspheres and form a monocellular
layer over all smooth surfaces. When rough surfaces are
present, even on larger particles, macrophages may morph
into giant cells in a frustrated attempt to phagocytize the
offending foreign body.
The third reaction to foreign material is the formation of
‘‘granulation tissue,’’ composed of macrophages, ﬁbro-
blasts, capillaries, and collagen that ﬁll the interstitial
spaces between the microspheres. The bovine collagen [1,
2] appears to maintain the separation between the micro-
spheres and facilitates tissue ingrowth (Fig. 2). Without
ArteFill’s collagen component the microspheres would
clump together—a phenomenon observed in other ﬁller
formulations using hyaluronic acid-based or methylcellu-
lose carriers [9].
Approximately 4 weeks after implantation the ArteFill
implant consists of 20% inert microspheres and 80%
granulation tissue. This ratio may vary at 4 weeks
depending on the volume of the material implanted
(Fig. 3). Subsequently, over time the connective tissue
matures through a natural process similar to scar formation
and the interstices are ﬁlled with ﬁbroblasts and autologous
collagen ﬁbers.
Histology at 3 months demonstrates that all of the
PMMA microspheres are completely encapsulated and are
surrounded by ﬁbroblasts and collagen ﬁbers. Macrophages
are rare and capillary in-growth is evident (Fig. 4).
Human histology after 10 years revealed strong bands
of mature collagen ﬁbers with fully intact capillary
vasculature surrounding intact PMMA microspheres
(which were dissolved by alcohol during histology pro-
cessing) (Fig. 5). In essence, the ArteFill injection serves
as a scaffold to promote a ‘‘living implant.’’ The PMMA
components of ArteFill become fully integrated into the
connective tissue, whether dermis or subdermal spaces. As
in normal tissue with sufﬁcient blood supply, there appears
to be constant turnover of cells, including ﬁbroblasts and
macrophages.
Fig. 2 For the ﬁrst few weeks the viscous collagen keeps the
microspheres apart to facilitate tissue ingrowth
Fig. 3 At 4 weeks all bovine collagen has been replaced by
autologous connective tissue and blood vessels are inﬁltrating the
implant
Fig. 4 Histology of ArteFill at 3 months: capillaries have inﬁltrated
the implant, which has become the patient’s own tissue (940)
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Unlike any other injectable ﬁller, ArteFill appears to
stimulate the patient’s own collagen production, which
then permanently envelopes the PMMA microspheres [10].
A key advantage of the collagen carrier appears to be its
viscosity [11], which keeps the microspheres evenly dis-
tributed and facilitates tissue ingrowth into the interstices.
The residual, inert, nonmetabolizable PMMA remains as a
scaffold to engender permanent autologous collagen
replacement of the injected bovine collagen carrier. Other
biologic ﬁller materials in commercial use for wrinkle
treatment and soft tissue augmentation are completely
metabolized within 6 months to 1 year [12].
A sustained tissue augmentation effect appears achiev-
able only with a nonabsorbable synthetic component to the
ﬁller (Fig. 6)[ 13, 14]. ArteFill’s 30–50-lm-diameter
PMMA microspheres (Fig. 1) seem to be the ideal size for
dermal injections—large enough to escape phagocytosis
[7] yet small enough to be smoothly delivered through a
ﬁne 26G or 30G needle.
There are other speciﬁc advantages to microspheres in
this size range. The smaller the microspheres (to the
threshold of phagocytosis), the larger their combined sur-
face area in a given volume and the greater the total
amount of new collagen deposition. Microspheres with a
diameter of 100 lm, for example, promote the ingrowth of
only about 56% connective tissue, whereas microspheres
with a mean diameter of 40 lm promote the ingrowth of
about 80% connective tissue [7]. The PMMA/collagen
ratio and the 30–50 lm PMMA microsphere sizing for
ArteFill are direct applications of these observations.
Two key features appear to prevent dissipation of Ar-
teFill into the surrounding ﬁne network of collagen ﬁbers
of the deep dermal and subdermal layers following injec-
tion: (1) The bovine collagen carrier acts as a glue,
embedding the microspheres and preventing their clumping
and allowing for new tissue ingrowth (Fig. 2). Thus, the
implant becomes part of the patient’s own soft tissue,
maintaining its integrity over years and decades. (2) The
30–50 lm microsphere size prevents both phagocytosis
with removal and also limits the PMMA particles from
entering the interstices of deep dermal ﬁbers, which have a
diameter of 10–15 lm[ 9], where muscle action might
disperse them.
In wrinkle treatment, the resulting structural support of
ArteFill’s six million microspheres per milliliter prevents
further wrinkling and folding. This allows the diminished
thickness of the corium to recover (Fig. 7). This wrinkle
recovery process appears similar to the well-known phe-
nomenon after facial palsy in older patients and in stroke
victims (or repeat Botox
  patients), whose facial wrinkles
and furrows on the paralyzed side completely disappear
over time simply as a result of the lack of movement.
Material and Methods
ArteFill Packaging
Each box of ArteFill contains 0.8 cc and 0.4 cc syringes.
The syringe can be equipped with a double stopper for use
in a Metered Dose Delivery (MDD) device that delivers
precise and consistent microdroplets. The PMMA micro-
spheres are suspended in a carrier of solubilized low anti-
genic bovine collagen 3.5% solution. The carrier collagen
contains the local anesthetic lidocaine (0.3%) for injection
comfort. The clear collagen solution allows the user to
detect any phase separation between solid microspheres
and viscous collagen. If phase separation is detected, the
Fig. 5 Human histology 10 years after Artecoll implantation shows
mature connective tissue: active ﬁbroblasts, microencapsulation of
each single microsphere, capillary ingrowth, and little foreign body
reaction (940)
Fig. 6 Blinded observer ratings according to the wrinkle assessment
scale [18]. The same effect of ArteFill is kept 5 years after injection
as after 6 months
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recommended. The product’s shelf life is currently
12 months.
Allergy Testing
Bovine collagen allergy testing is required to minimize the
risk of hypersensitivity reactions, especially in patients
who are being treated with a bovine collagen product for
the ﬁrst time. An intradermal collagen test injection in the
volar forearm 4 weeks prior to the planned ArteFill
implantation is standard. Reports of allergic reactions to
ArteFill are extremely rare. A recent ArteFill skin test
study involving 1,000 patients revealed only two positive
test results with elevated antibodies. This low allergy rate
(0.2%) to ArteFill’s bovine collagen carrier, compared to a
greater than 3% reactivity to the crosslinked bovine col-
lagen contained in Zyderm
 /Zyplast
 , may eventually
allow removal of FDA’s skin test requirement for ArteFill.
Although ArteFill collagen gel contains 0.3% lidocaine,
ﬁeld block local anesthetics may be used in very sensitive
patients. Other useful techniques include a topical anes-
thetic spray (PainEase
 ) or a 5% lidocaine cream [11]o r
others (EMLA
 , Betacaine
 , Topicaine
 ) applied 30 min
before the procedure.
At the beginning of the procedure, the physician should
ensure that the needle is not blocked by gently squeezing a
tiny drop of ArteFill out of its tip. Due to the microsphere
content, the viscosity of ArteFill is about three times higher
than that of collagen or hyaluronic acid and requires a bit
more force for extrusion. Extrusion forces are 32.7 N for
ArteFill compared to 11.2 N for Zyderm collagen.
Injection Technique
Tunneling Technique
Locating the correct plane for the injection of ArteFill
permanent ﬁller is of utmost importance. The thickness of
the facial dermis varies between 0.4 mm in lids and
1.2 mm in the forehead and cheeks (Fig. 8). In a deep
crease the thickness of the dermis may be reduced to only
one-third of its normal thickness [3]. The outer diameter of
Fig. 7 The ﬁrst ArteFill strand provides a soft ‘‘splint’’ beneath the
wrinkle. A second ‘‘splint’’ after 1–3 months causes the diminished
thickness of the dermis in a crease to recover its former thickness ([3]
with permission from Elsevier)
Fig. 8 The thickness of the dermis varies greatly in different areas of
the face (from [3])
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to estimate the thickness of the dermis. The facial dermis is
only about twice as thick as a 26G needle (Fig. 9).
With ﬁne blunt microneedles of 26G one cannot achieve
longitudinal penetration intradermally. Therefore, with this
type needle it is easy to establish the correct plane for
injection by manipulating the cannula tip along the dermis
from beneath. This technique minimizes trauma and pre-
vents bruising and intradermal ridges, especially in naso-
labial folds. It requires only a single cannula penetration
through a tiny stab incision [15].
For deep dermal injections in patients with facial lipo-
dystrophy syndrome (LDS), blunt needles of 23G or larger
will facilitate nudging venules and arterioles aside and
prevent bruising, intravascular deposition of ArteFill, and
potential embolism [15, 16].
The following speciﬁc steps for ArteFill injections have
yielded consistently good results:
• Prior to inserting the needle in the dermis, one may
stretch the skin tightly to create a ﬁrm surface. The
needle is inserted into the dermis at an approximately
10  angle, parallel to the length of the wrinkle or fold.
• While maintaining constant thumb pressure on the
plunger, insert the needle (with bevel either up or
down) into the skin at the dermal/subdermal interface
along the line of the wrinkle. ArteFill is implanted as
the needle is withdrawn along the course of the wrinkle
by placing a continuous strand of material under
consistent pressure (resistance will be noted) into the
junction of the reticular dermis and subcutaneous fat
(Fig. 9).
• If the needle placement is too superﬁcial, the gray of
the needle will be visible through the skin (Fig. 10) and
tissue blanching will be observed upon injection. This
indicates improper needle placement. The needle
should be withdrawn and reinserted one needle diam-
eter deeper. Blanching is a sign that the papillary plexus
is compressed. If blanching occurs, distribute the
implant into the surrounding dermis using ﬁngernail
massage.
• If needle placement is too deep, the needle will be felt
to ‘‘pop’’ the subcutaneous fat and no resistance will be
felt when injecting the ArteFill (Fig. 11).
• If the needle is in the correct plane, i.e., the junction of
the dermis and subdermal fat, it will be possible to pull
the dermis superﬁcially causing a ridge or push the
dermis deep causing a depression or groove (Fig. 12).
Fig. 9 The ‘‘tunneling technique’’: Note the relationship of dermal
thickness in a wrinkle and the diameter of a 26G needle—both are
around 0.4 mm. The ArteFill strand is delivered while withdrawing
the needle ([3] with permission from Elsevier)
Fig. 10 Incorrect intradermal needle placement
Fig. 11 The needle tip is too deep inside the subcutaneous fat and
implanted ArteFill will be wasted
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withdrawing the needle (Fig. 9). Using pressure on the
plunger during the forward movement of the needle, a
protruding droplet of ArteFill may create a ‘‘blunt
needle tip’’ and preserve some of the capillaries in its
way, e.g., it may prevent bruising.
• Immediately after implant placement, the injector
should palpate the implant by gently applying pressure
and eventually evenly massage with the ﬁngernail to
facilitate uniform distribution. Overly vigorous mas-
sage may spread ArteFill deeper into the fatty tissue
where it does not achieve the desired effect, and
massage may cause unwanted swelling and bruising.
In the nasolabial fold one should stay approximately
1 mm medial to the crease to prevent lateral dislocation of
the ArteFill implant by facial movement during the ﬁrst
few days following the injection. The nasolabial fold can
be divided and treated as three regions: the lower, middle,
and upper (subnasal triangle). Injection should begin in the
upper portion of the fold because of consequent anesthesia
of the lower parts of the nasolabial fold. In the upper region
the needle is fanned to eventually ﬁll a deep subnasal tri-
angle. The needle is inserted and advanced forward as far
as possible. While withdrawing (pulling back) the needle,
constant even pressure is applied on the plunger, depositing
and ‘‘anchoring’’ a uniform amount of ArteFill as one
proceeds (Fig. 9). Resistance should be felt during injec-
tion. The wrinkle should be lifted and improved by the end
of the injection.
With the exception of the soft vermilion, overcorrection
is difﬁcult if ArteFill is deposited in the correct plane, i.e.,
at the junction of the reticular dermis and subcutaneous fat.
The density of the reticular dermis prevents intrusion of the
material in excessive quantities.
The depth of needle placement and the quantity of Ar-
teFill used to correct a wrinkle varies depending on the
patient’s skin thickness and facial anatomy. If the patient
wants an optimal result, a hyaluronic acid product can be
injected into the reticular dermis above the ArteFill
‘‘splint’’ (Fig. 13). If the patient desires further correction
of the wrinkle, the same procedure may need to be repeated
until a satisfactory result is obtained (Fig. 7).
Serial Puncture Technique
Some injectors are skilled using the serial puncture tech-
nique developed for Zyderm/Zyplast [17]. In experienced
hands it may be as effective as threading. Proponents
maintain that it causes less bruising. An anesthetic cream
30 min before injection [11] may relieve the added dis-
comfort from multiple needle punctures.
Precautions and Aftercare
• The appearance of blanching indicates that the injection
occurred intradermally and therefore is too shallow.
• The implanted area should not be massaged because
this may adversely distribute the ArteFill support
‘‘splint’’ and increase swelling and bruising. In contrast
to temporary volume enhancers, ArteFill must not be
spread in the tissue but remain inside the tunnel in
which it was injected.
• The implants should be palpated for even distribution.
In case of lumpiness, pressure is applied by squeezing
the nasolabial fold between thumb and index ﬁnger.
• The treated fold should be taped with a 1-in. transparent
tape (Transpore
  or Blenderm
 ) for 3 days. The
purpose of the tape is to remind the patient not to
smile until the subdermal implant strands are ﬁxated.
ArteFill can be dislodged from the deep dermal
Fig. 12 The needle is placed correctly, one needle diameter deep in
the dermal–subdermal junction
Fig. 13 An optimal immediate result can be achieved by subdermal
injections of ArteFill (1.) and intradermal injections of hyaluronic
acid (2.) on top of it. ([3] with permission from Elsevier)
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facial muscle movement during the ﬁrst 3 days,
diminishing the expected result. To prevent this,
immobilization using tape is important during the ﬁrst
3 days.
• Patientsshouldbeadvisedthatthereissomeswellingfor
the ﬁrst 12–24 h. There is no indication for ice packs to
reduce swelling or bruising. Some edema of the implant
site is expected as a physiological necessity to allow
macrophagesandﬁbroblaststoinvadethetreatmentarea.
Prevention of smiling for 3 days is more important! Any
areas of light pink discoloration along the injection sites
(2–5 days) can be covered with makeup.
Progressive Enhancement
In most cases touch-up treatments can be administered
after 1–3 months. European experience with Artecoll has
shown that approximately 50% of patients will require a
second treatment to achieve full correction.
• When performing a touch-up procedure, the original
strand of implanted ArteFill can often be palpated with
the needle tip to determine location.
• The needle is inserted above the ﬁrst implant and below
the dermal crease in the deep dermis.
• New strands of ArteFill should be layered on top of the
original injected material. The new strands should not
be affected by facial movement because they obtain
support from the initial implant (Fig. 13).
The injected strands create a support structure (splint) for
the wrinkle from beneath and prevent further wrinkling. In
about 50 % of the patients, the original thickness of the
dermis recovers by itself within approximately 3 months
(Fig. 7).
Implant Volume
Grades I and II wrinkles [18] will require approximately
one strand of ArteFill (*0.2 cc). Grades III–V wrinkles
may need two to four strands (0.8 cc). Experience has
shown that overcorrection with ArteFill is almost impos-
sible. In the deep dermis beneath a wrinkle there is limited
space available that can be ﬁlled with ArteFill. In the right
plane, overcorrection would need increased pressure on the
plunger. However, the amount of internal scar formation
may differ from patient to patient.
Since connective tissue occupies the space between the
microspheres and eventually makes up 80% of the implant,
a few subsequent treatments (‘‘Progressive enhancement’’)
are recommended rather than one ‘‘bulk’’ treatment. For
example, a ﬁrst implantation of 0.4 cc of ArteFill will often
be sufﬁcient for forehead lines or glabellar frown lines, one
nasolabial fold, one upper or lower lip, both corners of the
mouth, both marionette lines, or two neck folds. A second
treatment may become necessary after 1–3 months in about
50% of the patients. In some patients desiring compre-
hensive treatment of acne scars, more than 30 cc of Arte-
Fill were used over time.
Appropriate deep dermal placement with small aliquots
of ArteFill and reevaluation of the results with a second
treatment session as needed would optimize results utiliz-
ing this unique product in the clinical setting.
Conclusion
ArteFill’s unique mechanism of action and the appropriate
injection techniques have been developed over the past two
decades with its predecessor product Artecoll. Certain side
effects and late complications of Artecoll [6] forced the
manufacturer in the U.S. to make radical changes in Ar-
teFill’s new formulation to achieve FDA approval as the
ﬁrst and only permanent dermal ﬁller in 2006.
ArteFill is approved for the correction of nasolabial
folds and has been used in over 15,000 patients since its
U.S. market introduction in February 2007. No serious side
effects have been reported to date according to the FDA’s
MAUDE reporting database (www.fda.gov/cdrh).
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